Description of Research: As part of 2 EU-funded consortia (PharmaSea and Ocean Medicines) we are focusing on novel secondary metabolite pathways from bacteria associated with marine invertebrates and sediments. Extract preparations from these isolates have shown anti-convulsant, anti-microbial or anti-inflammatory properties. Through genome sequencing and genetic engineering strategies in parallel with chemistry-guided isolation, we would like to link novel metabolites to the biosynthetic pathways encoding them.
Academic criteria: Applicants must have completed a PhD degree within no more than 5 years in a foundational discipline relevant to the topic. Applicants should have a strong publication record, interpersonal skills, project management experience, and be able to effectively conduct research as part of a multi-disciplinary team.
THE CLOSING DATE FOR APPLICATIONS IS 28 FEBRUARY 2017